alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
I 

118TH CONGRESS 

2D SESSION H. R. 7603 

To direct the Secretary of Defense to ensure that the audit of the financial 

statements of the Department of Defense for fiscal year 2024 is conducted using technology that uses artificial intelligence, and for other 

purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 8, 2024 

Mr. SCHWEIKERT introduced the following bill; which was referred to the 

Committee on Armed Services, and in addition to the Committee on Appropriations, for a period to be subsequently determined by the Speaker, 

in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To direct the Secretary of Defense to ensure that the audit 

of the financial statements of the Department of Defense 

for fiscal year 2024 is conducted using technology that 

uses artificial intelligence, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7603 IH

1 SECTION 1. USE OF TECHNOLOGY USING ARTIFICIAL IN2 TELLIGENCE TO FACILITATE AUDIT OF THE 

3 FINANCIAL STATEMENTS OF THE DEPART4 MENT OF DEFENSE FOR FISCAL YEAR 2024. 

5 (a) DEVELOPMENT OF AI TECHNOLOGY FOR AU6 DITS.—The Under Secretary of Defense (Comptroller) 

7 and the Inspector General of the Department of Defense 

8 shall jointly develop technology that uses artificial intel9 ligence for the purpose of facilitating audits of the finan10 cial statements of the Department. 

11 (b) USE OF TECHNOLOGY.—The Secretary of De12 fense shall ensure that— 

13 (1) the audit of the financial statements of the 

14 Department of Defense for fiscal year 2024, as re15 quired under section 240a of title 10, United States 

16 Code, is performed using the technology developed 

17 under subsection (a); and 

18 (2) the technology developed under subsection 

19 (a) is used to accelerate the retirement of older fi20 nancial management systems used by the Depart21 ment without compromising essential controls or 

22 generally accepted Government auditing standards. 

23 (c) TREATMENT OF SURPLUS FUNDS.—Any amounts 

24 identified in such audit as being surplus to the needs of 

25 the Department of Defense by reason of future valuation 

26 and accounting errors shall be rescinded and deposited in 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 7603 IH

1 the General Fund of the Treasury to be used for deficit 

2 reduction. 

3 (d) BRIEFING.—Not later than 180 days after the 

4 date of the enactment of this Act, the Secretary shall pro5 vide to the Committees on Armed Services of the Senate 

6 and House of Representatives a briefing on— 

7 (1) the progress of the audit of the financial 

8 statements of the Department of Defense for fiscal 

9 year 2024; and 

10 (2) the technology developed pursuant to sub11 section (a). 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
<PAGE>   1
                                                                  EXHIBIT 21.01




                       SUBSIDIARIES OF CORIXA CORPORATION


                              Chinook Corporation


                         Yakima Acquisition Corporation
# C_2018104EN.01002401.xml

| 19.3.2018 | EN | Official Journal of the European Union | C 104/24 |
| --- | --- | --- | --- |

19.3.2018

EN

Official Journal of the European Union

C 104/24

---

Judgment of the General Court of 1 February 2018 — Larko v Commission

(Case T-412/14) (1)

1

((Action for annulment - State aid - Sale of certain assets operated by an undertaking or belonging to that undertaking in the context of a privatisation programme - No economic continuity - Action by the beneficiary of the aid - No interest in bringing proceedings - Inadmissibility))

(2018/C 104/30)

Language of the case: Greek

Parties

Parties

Applicant: Larko Geniki Metalleftiki kai Metallourgiki AE (Athens, Greece) (represented by: I. Dryllerakis, N. Korogiannakis, I. Soufleros, E. Triantafyllou, G. Psaroudakis and E. Rantos, lawyers)

Applicant:

Defendant: European Commission (represented by: A. Bouchagiar, É. Gippini Fournier and B. Stromsky, Agents)

Defendant:

Re:

Re:

Application pursuant to Article 263 TFEU seeking annulment of Commission Decision C(2014) 1805 of 27 March 2014 on the State aid SA.37954 (2013/N) — Greece — Sale of certain assets of Larco General Mining & Metallurgical Company S.A. (OJ 2014 C 156, p. 1).

Operative part of the judgment

Operative part of the judgment

The Court:

| 1. | Dismisses the action as inadmissible; |
| --- | --- |

1.

Dismisses the action as inadmissible;

| 2. | Orders Larko Geniki Metalleftiki kai Metallourgiki AE to pay the costs. |
| --- | --- |

2.

Orders Larko Geniki Metalleftiki kai Metallourgiki AE to pay the costs.

---

(1)  OJ C 292, 1.9.2014.

1

---
##### 



Exhibit 32.1
 CERTIFICATION PURSUANT TO RULE 13a-14(b) OF
THE SECURITIES EXCHANGE ACT OF 1934
  (1)
    
    the Report fully complies with the requirements of Section 13(a) of the Securities
Exchange Act of 1934, as amended; and(2)
    
    the information contained in the Report fairly presents, in all material respects,
the financial condition and results of operations of the Company.
 August 8, 2007
    By:
    /s/ Charles F. ChampionCharles F. ChampionPresident and Chief Executive Officer August 8, 2007
    By:
    /s/ James A. BurkJames A. BurkChief Financial Officer
IN THE SUPREME COURT OF PENNSYLVANIA

EASTERN DISTRICT

COMMONWEALTH OF PENNSYLVANIA,

Respondent

v.

DANIEL A. BURRUS,

Petitioner

:

:

:

:

:

:

:

:

:

:

:

No. 83 EAL 2024

Petition for Allowance of Appeal 

from the Order of the Superior Court

ORDER

PER CURIAM

AND NOW, this 25th day of June, 2024, the Petition for Allowance of Appeal is 

DENIED.
# C_2017144EN.01004301.xml

| 8.5.2017 | EN | Official Journal of the European Union | C 144/43 |
| --- | --- | --- | --- |

8.5.2017

EN

Official Journal of the European Union

C 144/43

---

Order of the General Court of 8 March 2017 — Merck v EUIPO — Société des produits Nestlé (HEALTHPRESSO)

(Case T-747/14) (1)

1

((EU trade mark - Opposition proceedings - No need to adjudicate))

(2017/C 144/58)

Language of the case: English

Parties

Parties

Applicant: Merck KGaA (Darmstadt, Germany) (represented by: M. Best, U. Pfleghar and S. Schäffner, lawyers)

Applicant:

Defendant: European Union Intellectual Property Office (represented by: L. Rampini, acting as Agent)

Defendant:

Other party to the proceedings before the Board of Appeal of EUIPO intervening before the General Court: Société des produits Nestlé SA (Vevey, Switzerland) (represented by: A. Jaeger-Lenz, A. Lambrecht and S. Cobet-Nüse, lawyers)

Other party to the proceedings before the Board of Appeal of EUIPO intervening before the General Court:

Re:

Re:

Action brought against the decision of the First Board of Appeal of EUIPO of 7 August 2014 (Case R 1880/2013-1), relating to opposition proceedings between Société des Produits Nestlé SA and Merck KGaA.

Operative part of the order

Operative part of the order

| 1. | There is no longer any need to adjudicate on the action. |
| --- | --- |

1.

There is no longer any need to adjudicate on the action.

| 2. | Merck KGaA and Société des Produits Nestlé SA are ordered to bear their own costs and to, each, bear half of the costs incurred by the European Union Intellectual Property Office (EUIPO). |
| --- | --- |

2.

Merck KGaA and Société des Produits Nestlé SA are ordered to bear their own costs and to, each, bear half of the costs incurred by the European Union Intellectual Property Office (EUIPO).

---

(1)  OJ C 462, 22.12.2014.

1

---
CERTIFICATION PURSUANT TO
                            18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002



     In connection  with the Quarterly  Report of Tonga Capital Corporation
(the "Company") on Form 10-QSB for the period ending June 30, 2005 as filed with
the Securities  and Exchange  Commission on the date hereof (the  "Report").  I,
Jeffrey Ploen,  President,  Chief Executive Officer and Chief Financial Officer
of the company, certify, pursuant to 18 USC Section 1350, as adopted pursuant to
Section 906 of the  Sarbanes-Oxley Act of 2002, that to the best of my knowledge
and belief.

        (1)     The Report fully complies with the requirements of Section 13(a)
                or 15(d) of the Securities Exchange Act of 1934; and

        (2)     The information contained in the Report fairly presents, in all
                material respects, the financial condition and results of
                operations of the Company.




                                         /s/ Jeffrey Ploen
                                         --------------------------------
                                         Jeffrey Ploen, President
Dated: August 25, 2005
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.9 Limitations of exemptions from section 510(k) of the Federal Food, Drug, and Cosmetic Act (the act). The exemption from the requirement of premarket notification (section 510(k) of the act) for a generic type of class I or II device is only to the extent that the device has existing or reasonably foreseeable characteristics of commercially distributed devices within that generic type or, in the case of in vitro diagnostic devices, only to the extent that misdiagnosis as a result of using the device would not be associated with high morbidity or mortality. Accordingly, manufacturers of any commercially distributed class I or II device for which FDA has granted an exemption from the requirement of premarket notification must still submit a premarket notification to FDA before introducing or delivering for introduction into interstate commerce for commercial distribution the device when: ( a ) The device is intended for a use different from the intended use of a legally marketed device in that generic type of device; e.g., the device is intended for a different medical purpose, or the device is intended for lay use where the former intended use was by health care professionals only;
( b ) The modified device operates using a different fundamental scientific technology than a legally marketed device in that generic type of device; e.g., a surgical instrument cuts tissue with a laser beam rather than with a sharpened metal blade, or an in vitro diagnostic device detects or identifies infectious agents by using deoxyribonucleic acid (DNA) probe or nucleic acid hybridization technology rather than culture or immunoassay technology; or
( c ) The device is an in vitro device that is intended: ( 1 ) For use in the diagnosis, monitoring, or screening of neoplastic diseases with the exception of immunohistochemical devices;
( 2 ) For use in screening or diagnosis of familial or acquired genetic disorders, including inborn errors of metabolism;
( 3 ) For measuring an analyte that serves as a surrogate marker for screening, diagnosis, or monitoring life-threatening diseases such as acquired immune deficiency syndrome (AIDS), chronic or active hepatitis, tuberculosis, or myocardial infarction or to monitor therapy;
( 4 ) For assessing the risk of cardiovascular diseases;
( 5 ) For use in diabetes management;
( 6 ) For identifying or inferring the identity of a microorganism directly from clinical material;
( 7 ) For detection of antibodies to microorganisms other than immunoglobulin G (IgG) or IgG assays when the results are not qualitative, or are used to determine immunity, or the assay is intended for use in matrices other than serum or plasma;
( 8 ) For noninvasive testing as defined in § 812.3(k) of this chapter; and
( 9 ) For near patient testing (point of care).
[65 FR 2314, Jan. 14, 2000]
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1220 Acute kidney injury test system. ( a ) *Identification.* An acute kidney injury test system is a device that is intended to measure one or more analytes in human samples as an aid in the assessment of a patient's risk for developing acute kidney injury. Test results are intended to be used in conjunction with other clinical and diagnostic findings, consistent with professional standards of practice, including confirmation by alternative methods.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) Premarket notification submissions must detail an appropriate end user device training program that will be offered while marketing the device as part of your efforts to mitigate the risk of incorrect interpretation of test results.
( 2 ) As part of the risk management activities performed as part of your 21 CFR 820.30 design controls, you must document the appropriate end user device training program provided in your premarket notification submission to satisfy special control 21 CFR 862.1220(b)(1) that will be offered while marketing the device as part of your efforts to mitigate the risk of incorrect interpretation of test results.
( 3 ) Robust clinical data demonstrating the positive predictive value, negative predictive value, sensitivity and specificity of the test in the intended use population must be submitted as part of the premarket notification submission.
[82 FR 50072, Oct. 30, 2017]
§ 520.1631 Oxfendazole and trichlorfon paste. ( a ) *Specifications.* Each gram of paste contains 28.5 milligrams oxfendazole and 454.5 milligrams trichlorfon.
( b ) *Sponsor.* See 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use* — ( 1 ) *Amount.* 2.5 milligrams of oxfendazole and 40 milligrams of trichlorfon per kilogram of body weight.
( 2 ) *Indications for use.* The drug is used in horses for removal of bots (*Gasterophilus intestinalis,* 2nd and 3rd instars; *G. nasalis,* 3rd instar) and the following gastrointestinal worms: Large roundworms (*Parascaris equorum*), pinworms (*Oxyuris equi*), adult and 4th stage larvae; large strongyles (*Strongylus edentatus, S. vulgaris,* and *S. equinus*); and small strongyles.
( 3 ) *Limitations.* Horses maintained on premises where reinfection is likely to occur should be retreated in 6 to 8 weeks. Withholding feed or water before use is unnecessary. Administer with caution to sick or debilitated horses. Not for use in horses intended for food. Do not administer to mares during the last month of pregnancy. Trichlorfon is a cholinesterase inhibitor. Do not use this product in animals simultaneously with, or within a few days before or after treatment with or exposure to, cholinesterase-inhibiting drugs, pesticides, or chemicals. Consult your veterinarian for assistance in the diagnosis, treatment, and control of parasitism.
[50 FR 50291, Dec. 10, 1985, as amended at 61 FR 5506, Feb. 13, 1996; 78 FR 28825, May 20, 2014]
INDEPENDENT AUDITORS' CONSENT

                                                                      EXHIBIT 23

INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in this Registration Statement of
4Kids Entertainment, Inc. on Form S-8 of our report dated March 29, 2000,
appearing in the Annual Report on Form 10-K of 4Kids Entertainment, Inc. for the
year ended December 31, 1999.

/s/ Deloitte & Touche LLP
New York, New York
August 31, 2000


                                       8
39028.

#### INGRAM v. PHARR.

Frankum; Judge.

The plaintiff was injured when the automobile in which she was riding as a guest passenger struck the rear of the defendant’s automobile. The driver of the automobile in which the plaintiff was riding when she was injured was not made a party to this suit. The jury found for the defendant. Plaintiff’s motion for a new trial based on the usual general grounds was overruled. She appealed. *Held:*

“Questions of negligence, diligence, contributory negligence, and proximate cause are peculiarly matters for a jury, and a court should not take the place of the jury in solving them except in plain and indisputable cases.” *Southern Bakeries Co. v. White,*103 Ga. App. 146 (118 SE2d 724), and cases therein cited. We are of the opinion that the evidence was sufficient for the jury to conclude that the sole proximate cause of the plaintiff’s injury was the failure of the driver of the automobile, in which the plaintiff was riding as a guest passenger, to control his vehicle so as to avoid a collision with the defendant’s automobile when the defendant gave a signal indicating an intention to make a right turn but failed to turn his automobile completely off the paved highway.

The court did not err in overruling the plaintiff’s motion for a new trial on the general grounds only.

*Judgment affirmed.*

*Nichols, P. J., and Jordan, J., concur.*

*778Decided November 15, 1961.

*W. B. Mitchell, Bobby B. Mitchell,*for plaintiff in error.

*Harry A. Crawley,*contra.
I 

118TH CONGRESS 

2D SESSION H. R. 7475 

To require the GAO to conduct a study detailing the total cost of unused 

construction materials that were obtained for the construction of a border 

wall along the United States-Mexico border. 

IN THE HOUSE OF REPRESENTATIVES 

FEBRUARY 28, 2024 

Ms. VAN DUYNE introduced the following bill; which was referred to the 

Committee on Homeland Security 

A BILL 

To require the GAO to conduct a study detailing the total 

cost of unused construction materials that were obtained 

for the construction of a border wall along the United 

States-Mexico border. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Border Wall Waste 

5 Accountability Act’’. 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
2 

•HR 7475 IH

1 SEC. 2. GAO STUDY ON COST OF UNUSED CONSTRUCTION 

2 MATERIALS FOR BORDER WALL. 

3 Not later than 90 days after the date of the enact4 ment of this section, the Comptroller General of the 

5 United States shall submit to Congress a study detailing 

6 the total cost of unused construction materials that were 

7 obtained for the construction of a border wall along the 

8 United States-Mexico border. 

Æ 


kjohnson on DSK7ZCZBW3PROD with $$_JOB
# C_2014129EN.01002901.xml

| 28.4.2014 | EN | Official Journal of the European Union | C 129/29 |
| --- | --- | --- | --- |

28.4.2014

EN

Official Journal of the European Union

C 129/29

---

Action brought on 30 January 2014 — Swatch v OHIM — Panavision Europe (SWATCHBALL)

(Case T-71/14)

(2014/C 129/36)

Language in which the application was lodged: English

Parties

Applicant: Swatch AG (Biel, Switzerland) (represented by: P. González-Bueno Catalán de Ocón, lawyer)

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Other party to the proceedings before the Board of Appeal: Panavision Europe Ltd (Greenford, United Kingdom)

Form of order sought

The applicant claims that the Court should:

| — | Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 11 November 2013 given in Case R 470/2012-2. |
| --- | --- |

—

Annul the decision of the Second Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 11 November 2013 given in Case R 470/2012-2.

Pleas in law and main arguments

Applicant for a Community trade mark: The other party to the proceedings before the Board of Appeal

Community trade mark concerned: The word mark ‘SWATCHBALL’ for goods and services in Classes 9, 35, 41 and 42 — Community trade mark application No 6 543 524

Proprietor of the mark or sign cited in the opposition proceedings: The applicant

Mark or sign cited in opposition: International Registrations and Community trade mark registrations of the figurative mark containing the verbal element ‘swatch’ and the word mark ‘SWATCH’

Decision of the Opposition Division: Rejected the opposition

Decision of the Board of Appeal: Dismissed the appeal

Pleas in law: Infringement of Articles 8(1)(b) and 8(5) CTMR.

---
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3065 *Bordetella* spp. serological reagents. ( a ) *Identification. Bordetella* spp. serological reagents are devices that consist of antigens and antisera, including antisera conjugated with a fluorescent dye, used in serological tests to identify *Bordetella* spp. from cultured isolates or directly from clinical specimens. The identification aids in the diagnosis of diseases caused by bacteria belonging to the genus *Bordetella* and provides epidemiological information on these diseases. *Bordetella* spp. cause whooping cough (*Bordetella pertussis*) and other similiarly contagious and acute respiratory infections characterized by pneumonitis (inflammation of the lungs).
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25046, June 12, 1989; 66 FR 38791, July 25, 2001]
§ 809.3 Definitions. ( a ) *In vitro diagnostic products* are those reagents, instruments, and systems intended for use in the diagnosis of disease or other conditions, including a determination of the state of health, in order to cure, mitigate, treat, or prevent disease or its sequelae. Such products are intended for use in the collection, preparation, and examination of specimens taken from the human body. These products are devices as defined in section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act (the act) and may also be biological products subject to section 351 of the Public Health Service Act, including when the manufacturer of these products is a laboratory.
( b ) A *product class* is all those products intended for use for a particular determination or for a related group of determinations or products with common or related characteristics or those intended for common or related uses. A class may be further divided into subclasses when appropriate.
( c ) [Reserved]
( d ) *Act* means the Federal Food, Drug, and Cosmetic Act.
[41 FR 6903, Feb. 13, 1976, as amended at 45 FR 7484, Feb. 1, 1980; 89 FR 37445, May 6, 2024]